NCT04944030Recruiting
Clinico-biological Data Collection Study of Metastatic Lung Cancer
Prediction in Silico of Therapeutic Response in a Prospective Cohort Study of Metastatic Lung Cancer Patients
Source: ClinicalTrials.gov · Last updated 8 Dec 2025
Brief summary (registry, in English)
RATIONALE : Currently, the mechanisms associated with the response or resistance to treatment are poorly understood and are multifactorial. These mechanisms involve clinical and biological factors associated with the host and the tumor and possibly the patient's psycho-social environment. PURPOSE : This trial will assess the use of a prospective database dedicated to patients with breast cancers that contains clinical data as well as epidemiological, psychological, emotional, social, imaging, biological and biopathological data. These data will allow a creation of new modelling algorithms in order to predict response and resistance to treatment.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 15 Jun 2021
- Start date
- 24 Apr 2023
- Primary completion date
- Oct 2031
- Lead sponsor
- Institut Cancerologie de l'Ouest
- Diseases
- Lung cancer
- NCT number
- NCT04944030
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 24 Apr 2023 to the primary completion date, Oct 2031
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other malignancy treated within the last 3 years (except non-melanoma skin cancer or in situ carcinoma of the cervix)
Other
- Other neuroendocrine tumour than small cell or large cell carcinoma.
- Pregnant or nursing patient
- Individual deprived of liberty or placed under the authority of a tutor
- Impossibility to submit to the medical follow-up of this clinical trial for geographical, social or psychological reasons
Who the study is looking for
- Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening biopsy, blood sample and questionnaires
- 18 years old at time of written consent
- Patient with histologically confirmed lung cancer
- Lung cancer metastatic disease or locally advanced not eligible for local curative treatment intent
- Performance status ≤ 2 (according to WHO criteria)
- Indication of any systemic therapeutic strategy can be performed alongside this current cohort in accordance with national and / or international recommendations.
- Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- Patient must be affiliated to a Social Health Insurance
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut de Cancerologie de L'Ouest Coordinator of this site? Confirm its status | Angers | France | Recruiting |
| Institut de Cancérologie de l'Ouest Coordinator of this site? Confirm its status | Saint-Herblain | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.